Browse EV MemProt Atlas
Supporting publications (n)
Number of publications supporting the inclusion of this protein in EV MemProt Atlas.
EVMP confidence score
Annotation confidence score; open for threshold definitions.
Extremely high >= 0.85High >= 0.70Medium >= 0.55Low >= 0.40| UniProt ID | Protein names | Protein classification | Transmembrane count | Related Diseases | Mediation categories | Download | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| EXTL3 | O43909 | Exostosin-like 3 (EC 2.4.1.223) (EXT-related protein 1) (Glucuronyl-galactosyl-proteoglycan 4-alpha-N-acetylglucosaminyltransferase) (Hereditary multiple exostoses gene isolog) (Multiple exostosis-like protein 3) (Putative tumor suppressor protein EXTL3) | Disease related genesEnzymesHuman disease related genes | 1 | Immune mediationMetabolism mediationReceptor-signaling mediation | 5 | 0.25 | |||
| GLUT4 | P14672 | Solute carrier family 2, facilitated glucose transporter member 4 (Glucose transporter type 4, insulin-responsive) (GLUT-4) | Disease related genesMetabolic proteinsPotential drug targets | 12 | Type 2 diabetes mellitus | Clinical-translation mediationFusion and delivery mediationMetabolism mediation | 5 | 0.25 | ||
| HEG1 | Q9ULI3 | Protein HEG homolog 1 | Plasma proteinsPredicted membrane proteins | 1 | Adhesion and uptake mediationFusion and delivery mediationReceptor-signaling mediation | 5 | 0.25 | |||
| IGDC4 | Q8TDY8 | Immunoglobulin superfamily DCC subclass member 4 (Neighbor of punc e11) (Protein DDM36) (hDDM36) | Plasma proteinsPredicted membrane proteins | 1 | Other mediation | 5 | 0.25 | |||
| ITA5 | P08648 | Integrin alpha-5 (CD49 antigen-like family member E) (Fibronectin receptor subunit alpha) (Integrin alpha-F) (VLA-5) (CD antigen CD49e) [Cleaved into: Integrin alpha-5 heavy chain; Integrin alpha-5 light chain] | Cancer-related genesCD markersPlasma proteins | 1 | Allergic/hypersensitivity disorderAsthmaMultiple sclerosis | Adhesion and uptake mediationClinical-translation mediationFusion and delivery mediation | 5 | 0.25 | ||
| MRC1 | P22897 | Macrophage mannose receptor 1 (MMR) (C-type lectin domain family 13 member D) (C-type lectin domain family 13 member D-like) (Human mannose receptor) (hMR) (Macrophage mannose receptor 1-like protein 1) (CD antigen CD206) | CD markersFDA approved drug targetsPlasma proteins | 1 | COVID-19Type 2 diabetes mellitus | Adhesion and uptake mediationClinical-translation mediationImmune mediation | 5 | 0.25 | ||
| S26A2 | P50443 | Sulfate transporter (Diastrophic dysplasia protein) (Solute carrier family 26 member 2) | Disease related genesHuman disease related genesMetabolic proteins | 8 | Clinical-translation mediationFusion and delivery mediationMetabolism mediation | 5 | 0.25 | |||
| TSN14 | Q8NG11 | Tetraspanin-14 (Tspan-14) (DC-TM4F2) (Transmembrane 4 superfamily member 14) | Predicted membrane proteinsTransporters | 4 | Fusion and delivery mediationImmune mediationMetabolism mediation | 5 | 0.25 | |||
| ANTR1 | Q9H6X2 | Anthrax toxin receptor 1 (Tumor endothelial marker 8) | 1 | Adhesion and uptake mediationClinical-translation mediationFusion and delivery mediation | 4 | 0.25 | ||||
| AT1B2 | P14415 | Sodium/potassium-transporting ATPase subunit beta-2 (Adhesion molecule in glia) (AMOG) (Sodium/potassium-dependent ATPase subunit beta-2) | Metabolic proteinsPredicted intracellular proteinsPredicted membrane proteins | 1 | Adhesion and uptake mediationClinical-translation mediationFusion and delivery mediation | 4 | 0.25 | |||
| CD5 | P06127 | T-cell surface glycoprotein CD5 (Lymphocyte antigen T1/Leu-1) (CD antigen CD5) | CD markersPredicted intracellular proteinsPredicted membrane proteins | 1 | Adhesion and uptake mediationFusion and delivery mediationImmune mediation | 4 | 0.25 | |||
| CLD12 | P56749 | Claudin-12 | Predicted membrane proteins | 4 | Adhesion and uptake mediationFusion and delivery mediationReceptor-signaling mediation | 4 | 0.25 | |||
| DRB3 | P79483 | HLA class II histocompatibility antigen, DR beta 3 chain (MHC class II antigen DRB3) | 1 | Adhesion and uptake mediationFusion and delivery mediationImmune mediation | 4 | 0.25 | ||||
| KCNH2 | Q12809 | Voltage-gated inwardly rectifying potassium channel KCNH2 (Eag homolog) (Ether-a-go-go-related gene potassium channel 1) (ERG-1) (Eag-related protein 1) (Ether-a-go-go-related protein 1) (H-ERG) (hERG-1) (hERG1) (Potassium voltage-gated channel subfamily H member 2) (Voltage-gated potassium channel subunit Kv11.1) | 6 | Angina pectorisCardiac arrhythmiaGenetic cardiac arrhythmia | Clinical-translation mediationFusion and delivery mediation | 4 | 0.25 | |||
| LRC32 | Q14392 | Transforming growth factor beta activator LRRC32 (Garpin) (Glycoprotein A repetitions predominant) (GARP) (Leucine-rich repeat-containing protein 32) | 1 | Solid tumour/cancer | Adhesion and uptake mediationClinical-translation mediationFusion and delivery mediation | 4 | 0.25 | |||
| MRP2 | Q92887 | ATP-binding cassette sub-family C member 2 (EC 7.6.2.-) (EC 7.6.2.2) (EC 7.6.2.3) (Canalicular multidrug resistance protein) (Canalicular multispecific organic anion transporter 1) (Multidrug resistance-associated protein 2) | Cancer-related genesDisease related genesEnzymes | 17 | Clinical-translation mediationFusion and delivery mediationMetabolism mediation | 4 | 0.25 | |||
| NRP1 | O14786 | Neuropilin-1 (Vascular endothelial cell growth factor 165 receptor) (CD antigen CD304) | Cancer-related genesCD markersPlasma proteins | 1 | RetinopathySolid tumour/cancer | Adhesion and uptake mediationClinical-translation mediationFusion and delivery mediation | 4 | 0.25 | ||
| P2RX4 | Q99571 | P2X purinoceptor 4 (P2X4) (ATP receptor) (Purinergic receptor) | FDA approved drug targetsPredicted membrane proteinsTransporters | 2 | Clinical-translation mediationFusion and delivery mediationImmune mediation | 4 | 0.25 | |||
| P2RY8 | Q86VZ1 | S-geranylgeranyl-glutathione receptor P2RY8 (P2Y purinoceptor 8) (P2Y8) | Cancer-related genesG-protein coupled receptorsPredicted intracellular proteins | 7 | Receptor-signaling mediation | 4 | 0.25 | |||
| SATT | P43007 | Neutral amino acid transporter A (Alanine/serine/cysteine/threonine transporter 1) (ASCT-1) (Solute carrier family 1 member 4) | Disease related genesHuman disease related genesMetabolic proteins | 8 | Fusion and delivery mediation | 4 | 0.25 | |||
| SCN4B | Q8IWT1 | Sodium channel regulatory subunit beta-4 | Disease related genesFDA approved drug targetsHuman disease related genes | 1 | Clinical-translation mediationFusion and delivery mediation | 4 | 0.25 | |||
| SDK1 | Q7Z5N4 | Protein sidekick-1 | Predicted intracellular proteinsPredicted membrane proteins | 1 | Adhesion and uptake mediationReceptor-signaling mediation | 4 | 0.25 | |||
| TIE1 | P35590 | Tyrosine-protein kinase receptor Tie-1 (EC 2.7.10.1) | 1 | Fusion and delivery mediationReceptor-signaling mediation | 4 | 0.25 | ||||
| ADA22 | Q9P0K1 | Disintegrin and metalloproteinase domain-containing protein 22 (ADAM 22) (Metalloproteinase-disintegrin ADAM22-3) (Metalloproteinase-like, disintegrin-like, and cysteine-rich protein 2) | 1 | Adhesion and uptake mediation | 3 | 0.25 | ||||
| BY55 | O95971 | CD160 antigen (Natural killer cell receptor BY55) (CD antigen CD160) [Cleaved into: CD160 antigen, soluble form] | Adhesion and uptake mediationFusion and delivery mediationImmune mediation | 3 | 0.25 |